ClinicalTrials.gg

Program

mavacamten

Also written as “Mavacamten” and “MYK-461”.

Its studies are mostly in Cardiomyopathy, Hypertrophic · Anthrax, led by 2 companies.

Furthest: phase 4, since Oct 27, 202320 company-led studies, 3 open or runningNext primary completion: Dec 13, 2027 (phase 4)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Bristol-Myers Squibb183 open or runningphase 4since Oct 27, 2023Dec 19, 2014Dec 13, 2027phase 4 · NCT07004972
LianBio20 open or runningphase 3since Dec 13, 2021Oct 28, 2021none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 6 studies since Dec 19, 2014.

  1. Apr 5, 2018Phase 2 study in Cardiomyopathy, HypertrophicBristol-Myers Squibb · NCT03496168 · 13 enrolled · United States
  2. Oct 24, 2018Phase 3 study in Cardiomyopathy, HypertrophicBristol-Myers Squibb · NCT03723655 · 314 enrolled · United States, Belgium, Czechia and more
  3. Apr 7, 2020Phase 3 study in Cardiomyopathy, HypertrophicBristol-Myers Squibb · NCT04349072 · 112 enrolled · United States
  4. Feb 16, 2021Phase 2 study in Cardiomyopathy, Familial Restrictive, 3Bristol-Myers Squibb · NCT04766892 · 30 enrolled · United States, Canada
  5. Oct 28, 2021LianBio's first study: phase 1 study in Cardiomyopathy, HypertrophicNew to LianBioLianBio · NCT05135871 · 45 enrolled · China
  6. Dec 13, 2021Phase 3 study in Cardiomyopathy, HypertrophicLianBio · NCT05174416 · 81 enrolled · China
  7. Apr 1, 2022Phase 1 study in AnthraxBristol-Myers Squibb · NCT05320094 · 45 enrolled · United States
  8. May 2, 2022Phase 1 study in Cardiomyopathy, HypertrophicBristol-Myers Squibb · NCT05362045 · 158 enrolled · United States
  9. Jun 7, 2022Phase 3 study in Cardiomyopathy, HypertrophicBristol-Myers Squibb · NCT05414175 · 38 enrolled · Japan
  10. Sep 14, 2022Phase 3 study in Cardiomyopathy, HypertrophicBristol-Myers Squibb · NCT05582395 · 580 enrolled · United States, Australia, Austria and more
  11. Jan 31, 2023Phase 1 study in Cardiomyopathy, HypertrophicBristol-Myers Squibb · NCT05719805 · 84 enrolled · United States
  12. Oct 27, 2023Phase 4 study in Cardiomyopathy, HypertrophicBristol-Myers Squibb · NCT06112743 · 63 enrolled · United States, Argentina, Australia and more
  13. Feb 2, 2024Phase 3 study in Cardiomyopathy, HypertrophicBristol-Myers Squibb · NCT06253221 · 44 enrolled · United States, Australia, Canada and more
  14. May 26, 2025Phase 4 study in Symptomatic Obstructive Hypertrophic CardiomyopathyBristol-Myers Squibb · NCT07004972 · 50 enrolled · India

Ahead

  1. Dec 13, 2027Primary completion: phase 4 study in Symptomatic Obstructive Hypertrophic CardiomyopathyBristol-Myers Squibb · NCT07004972

TargetBeta

“Cardiac myosin inhibitor”ChEMBL 37, by rule

Other programs on the same 7 targets

ProgramCompanyFurthest phaseStudies
omecamtiv mecarbilruleCytokineticsphase 316
danicamtivruleBristol-Myers Squibbphase 37

Studies

All 20 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07004972Symptomatic Obstructive Hypertrophic Cardiomyopathy · India4Active, not recruitingBristol-Myers SquibbDec 13, 202750
NCT06253221Cardiomyopathy, Hypertrophic · United States, Australia, Canada and more3Active, not recruitingBristol-Myers SquibbNov 25, 202544
NCT06112743Cardiomyopathy, Hypertrophic · United States, Argentina, Australia and more4Active, not recruitingBristol-Myers SquibbJul 16, 202663
NCT05719805Cardiomyopathy, Hypertrophic · United States1CompletedBristol-Myers SquibbJul 25, 202384
NCT05582395Cardiomyopathy, Hypertrophic · United States, Australia, Austria and more3TerminatedBristol-Myers SquibbMar 6, 2025580
NCT05414175Cardiomyopathy, Hypertrophic · Japan3CompletedBristol-Myers SquibbNov 27, 202338
NCT05362045Cardiomyopathy, Hypertrophic · United States1CompletedBristol-Myers SquibbAug 19, 2022158
NCT05320094Anthrax · United States1CompletedBristol-Myers SquibbSep 11, 202245
NCT05174416Cardiomyopathy, Hypertrophic · China3CompletedLianBioMar 6, 202381
NCT05135871Cardiomyopathy, Hypertrophic · China1CompletedLianBioFeb 5, 202245
NCT04766892Cardiomyopathy, Familial Restrictive, 3 · United States, Canada2CompletedBristol-Myers SquibbFeb 26, 202430
NCT04349072Cardiomyopathy, Hypertrophic · United States3CompletedBristol-Myers SquibbFeb 7, 2022112
NCT03723655Cardiomyopathy, Hypertrophic · United States, Belgium, Czechia and more3CompletedBristol-Myers SquibbJan 16, 2026314
NCT03496168Cardiomyopathy, Hypertrophic · United States2CompletedBristol-Myers SquibbNov 9, 202313
NCT03470545Cardiomyopathy, Hypertrophic · United States, Belgium, Czechia and more3CompletedBristol-Myers SquibbMar 14, 2020251
NCT03442764Non-obstructive Hypertrophic Cardiomyopathy · United States2CompletedBristol-Myers SquibbJan 7, 202059
NCT02842242Cardiomyopathy, Hypertrophic · United States2CompletedBristol-Myers SquibbNov 201721
NCT02480296Healthy · Australia1CompletedBristol-Myers SquibbJul 201660
NCT02356289Cardiomyopathy, Hypertrophic · United Kingdom1CompletedBristol-Myers SquibbJul 201548
NCT02329184Cardiomyopathy, Hypertrophic · United States1CompletedBristol-Myers SquibbMar 201615

How it is read

Names in the registry

  • “Mavacamten”, 11 entries
  • “mavacamten”, 5 entries
  • “MYK-461”, 4 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.